Dr Garje on Selecting Between PARP Inhibitor Combinations in mCRPC
Rohan Garje, MD, discusses considerations when choosing between FDA-approved PARP inhibitor–based combinations for patients with mCRPC.
Rohan Garje, MD, discusses considerations when choosing between FDA-approved PARP inhibitor–based combinations for patients with mCRPC.
Supported by an independent educational grant from Genmab US, Inc. and AbbVie Join us for a symposium on bispecific antibodies for relapsed-refractory diffuse large B-cell…
Nivolumab plus concurrent chemoradiotherapy, followed by nivolumab plus ipilimumab, did not improve PFS in unresectable stage III NSCLC.
Rebecca Robinson, MRCP, MBBS, MRFSEM, Marylebone Health Group (CHHP), London, UK, comments on the role of exercise in cancer care, highlighting the importance of physical…
A retrospective analysis showed that metastasectomy plus radical nephrectomy could improve survival in patients with metastatic non–clear cell RCC.
Joaquim Bellmunt, MD, PhD, discusses the impact of enfortumab vedotin plus pembrolizumab on the treatment paradigm in first-line urothelial cancer.
Petros Grivas, MD, PhD, discusses the significance of the phase 3 JAVELIN Bladder 100, EV-302, and CheckMate 901 trials in urothelial cancer.
Jonathan E. Rosenberg, MD, discusses ongoing and planned research efforts to enhance the frontline and beyond urothelial cancer treatment landscape.
The phase 3 KeyVibe-010 trial of adjuvant vibostolimab plus pembrolizumab in patients with resected high-risk melanoma has been discontinued.
An abstract is unavailable.
Robert Wang, MD, discusses the presently limited utility of using molecular imagining with quantitative thresholds in distinguishing RCC from oncocytic renal masses.